ClinicalTrials.gg
CompletedNCT00259935Updated Nov 14, 2017

A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors

A Phase 1 interventional study of topotecan in Lung Cancer, Small Cell, sponsored by GlaxoSmithKline. Completed at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-14.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Oct 2004, registered Nov 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing topotecan in Small Cell Lung Carcinoma — 2 open to participants now, 4 under way, 2 of them phase 3. Topotecan · Small Cell Lung Carcinoma.

Enrollment
10th of 28
107 · median 44
Started
2004
with 6 others
Phase 1
8 of 29
none open now
Registered
13th of 29
by date
Lead sponsor
7 of 29
GlaxoSmithKline

Among the 29 studies testing topotecan in Small Cell Lung Carcinoma, this one is the 10th largest by enrollment of the 28 interventional ones that give a count, is one of 7 that started in 2004, is one of 8 in phase 1, and was the 13th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

2 of the 29 studies testing topotecan in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About topotecan

Topotecan: first FDA approval 1996 (HYCAMTIN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing topotecan in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

The purpose of this study is to determine the bioequivalence of the new oral capsule formulation to the currently used oral capsule formulation of topotecan.

03

Conditions studied

  • Lung Cancer, Small Cell

Keywords

  • Any Solid Tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with advanced solid tumors.
  • At least 4 weeks since last chemotherapy, radiotherapy, biologic therapy or surgery.
  • Subjects must be free of post-treatment side effects.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating
  • Subjects with uncontrolled emesis, regardless of etiology, active infection.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    All treated subjects

    Subjects were randomized to receive 4 mg of a new formulation and current formulation of oral topotecan on Days 1 and 8 of Course 1.

    Drug: topotecan

Interventions

06

What researchers measure

Primary outcomes

  1. Comparison of blood levels of topotecan following oral and IV dosing; blood samples will be drawn on Day 1 and Day 8 of Courses 1 and 2.

    Time frame: Days 1, 8

Secondary outcomes

  1. Assessment of clinical laboratory tests, cardiac monitoring and disease progression. Comparison of blood levels of topotecan when taken orally with and without food; blood samples will be drawn on Day 1

    Time frame: Up to 38 days

07

Study locations

8 sites
  • GSK Investigational Site
    Lebanon, New Hampshire 03756, United States
  • GSK Investigational Site
    Bronx, New York 10461, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19111, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Morgantown, West Virginia 26506, United States
  • GSK Investigational Site
    Amsterdam, 1066 CX, Netherlands
  • GSK Investigational Site
    Utrecht, 3584 CX, Netherlands
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2004 to primary completion in Jul 2007, 33 months.

Of 111 industry-sponsored phase 1 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 63. This study's 33 months is below that.

Counting every sponsor, half of 143 studies reached it within 46 months; a quarter within 29 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2005
First posted
Dec 1, 2005
StartActual
Oct 4, 2004
Primary completionActual
Jul 5, 2007
CompletionActual
Jul 5, 2007
Last update
Nov 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00259935
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 1, 2005
Start date
Oct 4, 2004
Primary completion
Jul 5, 2007
Completion
Jul 5, 2007
Last update
Nov 14, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Topotecan

Start the discussion